Alzheimer’s Disease – Special Topics – Special Topics: Physician Awareness, Perceptions, and Use of Leqembi (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS covering the drug in line with its label and broadening reimbursement of PET scans used to establish diagnoses and determine treatment eligibility, Leqembi is poised to capitalize on the unfulfilled potential for an AD DMT. However, logistic hurdles on the path to diagnosis and treatment initiation must be overcome to unlock the full potential of a DMT in the AD market. This survey-based report assesses awareness, perceptions, and usage of the drug among U.S. neurologists and geriatricians who manage patients with early AD as well as unspecified dementia or unspecified mild cognitive impairment. With additional DMTs poised to reach the market in 2024, the data will provide insight into drivers and constraints on the use of Leqembi and similar agents and will highlight opportunities to support current and future prescribers to drive uptake.
Questions answered
- What are the awareness of, familiarity with, and perceptions of Leqembi among U.S. neurologists and geriatricians in year one of its launch?
- What is the general perception of Leqembi as a treatment for AD among neurologists and geriatricians, and how has the approval of Leqembi impacted their practices?
- How do the clinical and nonclinical attributes of Leqembi influence physicians’ willingness to prescribe it?
- To how many patients have they prescribed the drug? How many patients are inquiring about it?
- What types of assessments are physicians completing at follow-up appointments?
- What are the main obstacles holding physicians back from administering Leqembi to more of their AD patients? Why have some physicians not yet used Leqembi for AD, and when do they plan to?
- What factors contribute to treatment discontinuation?
Product description
Clarivate’s Special Topics reports use quantitative and/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help gauge competitors in shaping their market strategies, identifying potential areas for differentiation, and physician’s receptivity.
Vaneet Kaur, M.P.T., is an associate healthcare research & data analyst on the CNS/Ophthalmology team at Clarivate. She has substantial experience in market research and has developed expertise in analyzing market trends and emerging pipelines, conducting primary and secondary research, and providing valuable insights. She has a Master’s degree in physiotherapy with a sports specialization from Amity University, complemented by an MBA in marketing management from SVKM NMIMS, showcasing her profound understanding of healthcare and its related industries.